Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Prelude Therapeutics (PRLD) Shares Outstanding (2023 - 2026)

Prelude Therapeutics' Shares Outstanding history spans 4 years, with the latest figure at $14.7 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding fell 66.22% to $14.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.7 million, a 66.22% decrease, with the full-year FY2025 number at $48.2 million, up 275.29% from a year prior.
  • Shares Outstanding hit $14.7 million in Q1 2026 for Prelude Therapeutics, down from $48.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for PRLD hit a ceiling of $48.2 million in Q4 2025 and a floor of $12.9 million in Q2 2024.
  • Historically, Shares Outstanding has averaged $37.6 million across 4 years, with a median of $42.2 million in 2024.
  • Biggest five-year swings in Shares Outstanding: crashed 69.45% in 2024 and later skyrocketed 275.29% in 2025.
  • Tracing PRLD's Shares Outstanding over 4 years: stood at $42.1 million in 2023, then crashed by 69.45% to $12.9 million in 2024, then skyrocketed by 275.29% to $48.2 million in 2025, then plummeted by 69.46% to $14.7 million in 2026.
  • Business Quant data shows Shares Outstanding for PRLD at $14.7 million in Q1 2026, $48.2 million in Q4 2025, and $43.8 million in Q3 2025.